Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen, M TWhalen, JBuguth, B SeewoodharryVallejo-Aparicio, L ANaya, I PAsukai, YAlcázar-Navarrete, BMiravitlles, MGarcía-Río, FRisebrough, N A2023-01-252023-01-252019-01-28http://hdl.handle.net/10668/13475Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.research article30691468open access10.1186/s12931-019-0985-21465-993XPMC6348614https://doi.org/10.1186/s12931-019-0985-2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614/pdf